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utive patients, the (mean  SE) GFR was 4.0  0.2 mL/min/Remission and regression in the nephropathy of type 1 diabetes
year during the investigation period.when blood pressure is controlled aggressively.
Conclusions. Our study suggests that aggressive antihyper-Background. Diabetic nephropathy is a chronic, progressive
tensive treatment in type 1 diabetic patients can induce remis-kidney disease with a mean rate of decline of in glomerular
sion and regression in a sizable fraction of patients with diabeticfiltration rate (GFR) of 10 to 12 mL/min/year (natural history).
The introduction of aggressive antihypertensive treatment has nephropathy. Lower arterial blood pressure, reduced albumin-
improved the renal prognosis during the last decades. To exam- uria, and better glycemic control were predictors of regression
ine whether remission and regression of diabetic nephropathy of diabetic nephropathy.
are possible in type 1 diabetic patients, we analyzed data from
a prospective observational cohort study that was started in 1983.
Methods. We measured GFR with a 51Cr-EDTA plasma
Through decades, diabetic nephropathy has been re-clearance technique every year for seven years (range 3 to 14
years) in 301 consecutive type 1 diabetic patients with diabetic garded as an irreversible and rapidly progressive disease
nephropathy. Diabetic nephropathy was diagnosed clinically with high morbidity and mortality [1, 2]. The natural
if the following criteria were fulfilled: persistent albuminuria history of diabetic nephropathy, that is, without antihy-
200 g/min, presence of diabetic retinopathy, and no evi-
pertensive treatment, is characterized by arterial blooddence of other kidney or renal tract disease. Blood pressure,
pressure elevation, increasing albuminuria and a relent-albuminuria, glycosylated hemoglobin A1c, and serum choles-
terol were measured every three to four months during the less mean rate of decline in glomerular filtration rate
study. In total, 271 patients received antihypertensive treat- (GFR) of approximately 10 to 12 mL/min/year [3–5].
ment, 179 patients predominantly with angiotensin-converting The average survival time from onset of proteinuria wasenzyme inhibitors. Remission was defined as albuminuria200
only five to seven years before the introduction of antihy-g/min sustained for at least one year and a decrease of at
pertensive treatment in these patients [1, 6]. The progno-least 30% from preremission levels (surrogate endpoint), and
regression as a rate of decline in GFR (GFR) equal to the sis has improved, however, over the last decades, mainly
natural aging process:1 mL/min/year during the entire obser- because of a more aggressive treatment of arterial hyper-
vation period (principal end point).
tension [3, 7–13]. Even though the progression can beResults. The total number of patients who obtained remis-
somewhat halted, diabetic nephropathy is still regardedsion was 92 (31%), with a duration of remission of [median
(range)] 3.4 (1.0 to 14.1) years, and regression 67 (22%). The as an irreversible and inexorable progressive disease [2].
patients were stratified in quintiles by the average value of Recently, studies dealing with near normalization of
office mean arterial blood pressure (mean SE): 93 0.5, 99 blood glucose levels have challenged the concept of re-0.2, 103 0.1, 107 0.2, and 113 0.4 mm Hg. The prevalence
lentless progression by demonstrating reversibility of di-of patients obtaining remission/regression was 58/42, 33/32, 25/
abetic glomerular lesions in a small number of patients11, 20/20, and 17/7% in each quintile, respectively. Spontaneous
remission and regression occurred in 10 and 14 patients from with urinary albumin excretion ranging from normal to
the persistent normotensive group (N  30), none of whom clearly abnormal levels [14, 15]. Furthermore, remission
had ever received antihypertensive treatment. In all 301 consec-
of nephrotic range proteinuria, defined as remission from
proteinuria above 3500 mg per 24 hours to below 1000
1 See Editorial by Steffes, p. 378 mg per 24 hours and sustained below 1500 mg per 24
hours for at least six months and until the end of the
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trial, has been demonstrated in a subset of patients frompressure, diabetic nephropathy, glomerular filtration rate, renoprotec-
tion, progressive renal disease. the Captopril Study by Hebert et al [16]. To evaluate
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diabetic patients suffering from diabetic nephropathy, tion [18]. The mean variability in GFR of each patient
from day to day was 4%. Results are standardized forwe analyzed data from a long-term prospective observa-
tional study, started in 1983, in a consecutive cohort of 1.73 m2 body surface, using the patients’ surface area at
the start of the study throughout.301 type 1 diabetic patients with diabetic nephropathy.
Albuminuria was measured in urine collections ob-
tained during the four-hour clearance period [17] and
METHODS
at each visit to the outpatient clinic in 24-hour urine
Patients collections at an average of three to four times a year.
Glycosylated hemoglobin A1c was measured from venousThe patients and procedures have been described in
detail previously [17]. In brief, since 1983 at the Steno blood samples by isoelectric focusing and high-perfor-
mance liquid chromatography (HPLC) [17]. The normalDiabetes Center, all type 1 diabetic patients with ne-
phropathy have had their kidney function monitored range was 4.1 to 6.4%. Serum cholesterol was measured
with standard laboratory techniques every second year.with one yearly determination of GFR. We consecutively
included all type 1 diabetic patients who had a minimum Arterial blood pressure was measured at each visit to
the outpatient clinic and during GFR investigation withof three years of follow-up (N 301). Of the 301 patients,
196 had a yearly GFR measurement performed, and 97 a standard mercury sphygmomanometer and an appro-
priate cuff size. The measurements were performedpatients had more than one yearly GFR measurement
per year, while 8 patients had less than one GFR mea- twice, on the right arm, after at least 10 minutes of rest,
and the measurements were averaged. Diastolic bloodsurement per year during the observation period. The
recruitment period for our prospective cohort study pressure was recorded at the disappearance of Korotkoff
sounds (phase V). Arterial hypertension was diagnosedended in 1997. At the end of the study, 221 patients
remained in the study. Eighteen patients had progressed according to the World Health Organization’s criteria
(160/95 mm Hg) until 1995 and thereafter accordingto end-stage renal failure. Forty patients had died, and
22 patients had moved away from Copenhagen. Diabetic to the American Diabetes Associations criteria (140/90
mm Hg) [19]. All patients visited the outpatient clinicnephropathy was diagnosed clinically if the following
criteria were fulfilled: persistent albuminuria 200 g/ every three to four months during the study, and at each
visit blood glucose concentration, glycosylated hemoglo-min in at least two out of three consecutive 24-hour urine
collections, the presence of diabetic retinopathy, and the bin A1c, albuminuria, blood pressure, and body weight
were monitored, and the insulin dose and antihyperten-absence of any clinical or laboratory evidence of other
kidney or renal tract disease [7]. A total of 271 patients sive treatment were adjusted.
Retinopathy was assessed at least yearly after pupil-were treated with antihypertensive medication, 179 pa-
tients predominantly with angiotensin-converting enzyme lary dilation by ophthalmoscopy. After 1991 it was as-
sessed by fundus photography, and graded as nil, simplex(ACE) inhibitors. Patients were classified as taking a
class of antihypertensive agent if the drug was prescribed or proliferative diabetic retinopathy.
for more than 50% of the individual follow-up time.
Definitions used in the present studySeventeen percent of the patients received monotherapy.
Forty-seven percent received two agents. Thirty percent All patients had diabetic nephropathy as defined pre-
viously in this article and were categorized based onreceived three agents, and 6% were treated with four or
more antihypertensive drugs. During the entire follow- values during the entire follow-up period as follows.
Remission of diabetic nephropathy. A decrease in albu-up period, we strived to keep blood pressure below
140/90 mm Hg. Thirty patients remained normotensive— minuria to below 200g/min (the microalbuminuric range)
[2] in at least two out of three consecutive 24-hour urinewith arterial blood pressure below 140/90 mm Hg—with-
out antihypertensive treatment before and throughout collections that was sustained for at least one year during
follow-up, with a decrease of at least 30% from preremis-the observation period, that is, genuine normotensive
patients. The local ethical committee approved the ex- sion levels.
Regression of diabetic nephropathy. A rate of declineperimental design, and all patients gave their informed
consent. in GFR equal to or less than 1 mL/min/year during the
entire observation period. This decline is equivalent to
Procedures the natural aging process in nondiabetic patients without
kidney disease [20]. Linear regression analysis was usedThe measurement of GFR was performed 3 to 24 times
(median 8) in each patient during a follow-up period of to determine the slope of GFR for each patient.
Spontaneous remission and regression. Remission and3 to 14 years (median 7). GFR was measured after a
single intravenous injection of 3.7 MBq 51Cr-EDTA by regression, as defined previously, in genuine normoten-
sive patients not receiving blood pressure-lowering agentsdetermination of the radioactivity in venous blood sam-
ples taken 180, 200, 220, and 240 minutes after the injec- before or during follow-up.
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Table 1. Remission in 301 type 1 diabetic patients suffering from diabetic nephropathy
Remission group No remission group
N  92 N  209 P value
Baseline
Sex males/females 49/43 143/66 0.05
Height cma 1729 1738 NS
Age yearsa 3712 3611 NS
Duration of diabetes year a 228 228 NS
Retinopathy simple/proliferative 24/68 75/134 NS
Smoking yes/no 47/45 117/92 NS
Systolic blood pressure mm Hga 13718 14119 NS
Diastolic blood pressure mm Hga 849 869 NS
Mean arterial blood pressure mm Hga 10210 10411 0.05
Albuminuria lg/minb,c 308 822
(45–4155) (205–6176) —
Glycosylated hemoglobin A1c %a 9.21.4 9.41.5 NS
Glomerular filtration rate mL/min/1.73 m2a 9028 8828 NS
During the follow-up periodd
Rate of decline in glomerular filtration rate
during entire observation period mL/min/yeare 2.20.3 4.80.3 0.001
Systolic blood pressure mm Hge 1371.4 1450.9 0.001
Diastolic blood pressure mm Hge 810.6 840.4 0.001
Mean arterial blood pressure mm Hge 1000.8 1050.5 0.001
Albuminuria lg/minb 181 795
(11–966) (221–5152) —
Glycosylated hemoglobin A1c %e 9.10.1 9.30.1 NS
Serum cholesterol mmol/Le 5.40.1 5.80.1 0.01
Antihypertensive treatment nil/non-ACE-I/ACE-I 10/26/56 20/66/123 NS
Observation time yearsb 10.0 6.2
(3.1–13.8) (3.0–14.0) 0.01
ACE-I is angiotensin-converting enzyme inhibitors.
Clinical and laboratory data at baseline and during follow-up are shown.
Data are N, a means  SD, b medians (range) and e means  SEM.
c Some patients with previously persistent albuminuria receiving antihypertensive treatment had baseline albuminuria below 200 g/min
d In each patient, all measurements performed during the entire follow-up period were used to calculate mean/median values
Statistical analysis Thirty-three patients (11%) fulfilled both criteria. In the
remission group, 36% achieved regression and 64% didResults are expressed as means  SEM, with means 
not. In the regression group, 49% obtained remissionSD being used for descriptive information. Albuminuria
and 51% did not. Spontaneous remission and regressionis given as median (range) and is logarithmically trans-
occurred in 10 and 14 patients from the persistent normo-formed before analysis because of the positively skewed
tensive group (N  30), none of whom had ever receiveddistribution. In each patient, all measurements performed
antihypertensive treatment. In the remission group, theduring the entire follow-up period were used to calculate
preremission level of albuminuria in was 692 (292 tomean values. Linear regression analysis, least-square
4828) g/min, and the duration of remission was 3.4method, was used to determine the slope of GFR for each
(1.0 to 14.1) years. The number of urine samples in thepatient. In normally distributed variables, a comparison
remission period was 16 (3 to 84). Fifty patients remainedbetween groups was performed by an unpaired Student
in remission to the end of follow-up, follow-up time oft test. In non-normally distributed continuous variables,
8.0 (3.1 to 13.8) years, a duration of remission of 4.8 (1.0a Mann–Whitney test was used for comparison between
to 14.1) years, while 42 patients relapsed from remission,groups. A chi-square test was used to compare frequen-
follow-up time of 10.9 (3.1 to 13.5) years, duration ofcies.
remission of 2.6 (1.0 to 8.4) years. The demographic,A logistic regression analysis was performed with re-
clinical, and laboratory characteristics of the patientsgression of nephropathy as outcome variable. All calcu-
obtaining remission opposed to the patients not fulfillinglations were performed with a commercially available
these criteria are shown in Table 1. By definition, albu-program (SPSS 10.0; SPSS Inc., Chicago, IL, USA).
minuria was reduced in the remission group. Patients
obtaining remission had a female preponderance (P 
RESULTS 0.05), but were otherwise similar to the patients in the
no-remission group at baseline. There was no differenceOf the 301 consecutive type 1 diabetic patients with
diabetic nephropathy, 92 patients (31%) obtained remis- in GFR at entry of the study between groups (NS). In
contrast, patients in the remission group had a signifi-sion. Sixty-seven patients (22%) achieved regression.
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Table 2. Regression in 301 type 1 diabetic patients suffering from diabetic nephropathy
Remission group No remission group
N  67 N  234 P value
Baseline
Sex males/females 39/28 153/81 NS
Height cma 1739 1728 NS
Age yearsa 3711 3611 NS
Duration of diabetes yearsa 238 228 NS
Retinopathy simplex/proliferative 27/40 72/162 NS
Smoking yes/no 42/25 122/112 NS
Systolic blood pressure mm Hga 13516 14019 0.05
Diastolic blood pressure mm Hga 839 869 0.01
Mean arterial blood pressure mm Hga 10010 10411 0.01
Albuminuria lg/minb,c 378 749 —
(77–3310) (45–6176) —
Glycosylated hemoglobin A1c %a 9.01.1 9.41.5 0.05
Glomerular filtration rate mL/min/1.73 m2a 9122 8829 NS
Rate of decline in glomerular filtration rate
during entire observation period mL/min/yeare 	0.70.2 5.40.2 0.001
Systolic blood pressure mm Hge 1381.5 1440.9 0.001
Diastolic blood pressure mm Hge 800.7 840.4 0.001
Mean arterial blood pressure mm Hge 990.8 1040.5 0.001
Albuminuria lg/minb 319 620 —
(12–1536) (11–5152)
Glycosylated hemoglobin A1c %e 8.70.1 9.40.1 0.001
Serum cholesterol mmol/Le 5.30.1 5.80.1 0.001
Antihypertensive treatment nil/non-ACE-I/ACE-I 14/20/33 16/72/146 0.01
Observation time yearsb 10.0 6.5
(3.2–13.4) (3.0–14.0) NS
ACE-I is angiotensin-converting enzyme inhibitors.
Clinical and laboratory data at baseline and during follow-up are shown.
Data are N, a means  SD, b medians (range), and c means  SEM
c Some patients with previously persistent albuminuria receiving antihypertensive treatment had baseline albuminuria below 200 g/min
d In each patient, all measurements performed during the entire follow-up period were used to calculate mean/median values.
cantly lower rate of decline in GFR of 2.2 mL/min/year hemoglobin A1c (P 0.001), and serum cholesterol (P
0.001). In the regression group, patients treated predomi-as compared with the no-remission group, GFR 4.8
mL/min/year (P  0.001). Furthermore, mean arterial nantly with an ACE inhibitor had a mean arterial blood
pressure of 100 mm Hg as compared with 101 mm Hgblood pressure (P  0.001) and serum cholesterol (P 
0.01) were lower in the remission group during the obser- in patients on non-ACE inhibitor antihypertensive treat-
ment (NS). In the no-regression group, mean arterialvation period. The duration of diabetes at baseline was
identical, 22 versus 22 years in the two groups. In the blood pressure was 105 mm Hg in the ACE inhibitor-
treated patients and 104 mm Hg in patients on otherremission group, patients treated predominantly with an
ACE inhibitor had a mean arterial blood pressure of antihypertensive agents (NS). The proportion of genuine
normotensive patients was larger (P 0.01) as compared100 mm Hg as compared with 101 mm Hg in patients
taking non-ACE inhibitor antihypertensive treatment with the no-regression group.
The mean GFR in all 301 patients was 4.0  0.2 mL/(NS). In the no-remission group, mean arterial blood
pressure was 106 mm Hg in the ACE inhibitor-treated min/year during the investigation period. The 30 genuine
normotensive patients had a significantly lower GFRpatients and 104 mm Hg in patients on other antihyper-
tensive agents (NS). The remission group had a longer as compared with the hypertensive patients, 1.9  0.5
vs. 4.3  0.3 mL/min/year (P  0.01).duration of follow-up (P  0.01). The occurrence of
remission was not dependent on observation time from The relationships between blood pressure and the
prevalence of patients obtaining remission or regressiononset of persisting proteinuria.
Table 2 shows the demographic, clinical, and labora- are presented in Figures 1 and 2. Patients are separated
into quintiles of mean arterial blood pressure duringtory characteristics of patients achieving regression ver-
sus patients not achieving regression. By definition, follow-up.
A logistic regression analysis, including sex, age, dura-GFR was lower in the regression group, even though no
difference in GFR at entry was apparent. The following tion of diabetes, smoking, degree of retinopathy, class
of antihypertensive treatment, and mean values of meanvariables, measured during the whole observation pe-
riod, were lower in the regression group: mean arterial arterial blood pressure, log10(albuminuria), hemoglobin
A1c, and serum cholesterol during follow-up, showed sig-blood pressure (P  0.001), albuminuria (P  0.001),
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Fig. 1. Prevalence of remission, defined as urinary albumin excretion Fig. 2. Prevalence of regression, defined as rate of decline in GFR 1
rate 200 g/min that is sustained for at least one year during follow- mL/min/year, in 301 type 1 diabetic patients with diabetic nephropathy.
up, in 301 type 1 diabetic patients with diabetic nephropathy. Symbols Symbols are: ( ) no antihypertensive treatment; () antihypertensive
are: ( ) no antihypertensive treatment; () antihypertensive treatment. treatment.
nificant associations between regression of nephropathy to conclude the following: “Diabetic nephropathy is irre-
versible in humans. No cases of recovery or cure haveand mean arterial blood pressure, albuminuria, and he-
moglobin A1c. The adjusted odds ratio (95% CI) for been reported in the literature. Once the clinical signs of
nephropathy have become manifest, the natural course isregression associated with a 10 mm Hg decline in mean
arterial blood pressure was 2.14 (1.33 to 3.44), with a inexorably progressive to death.” The same conclusion
was obtained based on a much larger cohort study at ourtenfold lowering in albuminuria: 2.79 (1.35 to 5.69) and
with a reduction of 1% in hemoglobin A1c: 2.00 (1.46 to diabetes center in Copenhagen [6]. The average survival
time from onset of diabetic nephropathy to death was2.73) (P  0.001).
Of the 271 patients treated with antihypertensive agents, five to seven years in both studies [1, 6]. The present
and previous studies [3, 7–13] have clearly documented116 patients [43% (95% CI, 37 to 49)] achieved a mean
systolic blood pressure below 140 mm Hg during the that antihypertensive treatment has a renoprotective ef-
fect, which may be so powerful that end-stage renal dis-follow-up period. In 226 patients [83% (79 to 87)], dia-
stolic blood pressure was below 90 mm Hg, whereas 108 ease can be prevented in a sizable fraction of the type
1 diabetic patients with diabetic nephropathy. Further-patients [40% (34 to 46)] achieved a blood pressure below
140 mm Hg systolic and 90 mm Hg diastolic. Correspond- more, long-term (10 years) normoglycemia, as obtained
with pancreas transplantation in eight patients, can in-ingly, 183 patients [68% (62 to 74)] had a mean arterial
blood pressure below 107 mm Hg during follow-up. duce a reversal of lesions of diabetic glomerulopathy
[15]. Except from this study, the only treatment modality
that can reduce albuminuria and rate of decline in GFR,
DISCUSSION
postpone end-stage renal disease, and prolong life is
Our prospective observational study suggests that ag- effective antihypertensive treatment [21].
gressive antihypertensive treatment can induce remis- Recently, the terms “remission” and “regression” have
sion and regression in a sizable fraction of type 1 diabetic been applied for the outcome of different chronic kidney
patients with diabetic nephropathy. The observed fre- diseases [16, 22–24]. Since no generally accepted defini-
quency of remission and regression must be regarded as tions have been established in diabetic nephropathy, we
conservative, since only 40% of patients treated with have chosen very conservative and strict criteria in order
antihypertensive agents achieved a blood pressure below to obtain valid prognostic information in relationship to
140/90 mm Hg. The prevalence of remission and regres- a surrogate end point (microalbuminuria) and a principal
sion increased with lower levels of blood pressure. Pa- end point (rate of decline in GFR).
tients in regression as defined in our study are unlikely To evaluate whether remission and regression of dia-
to progress to end-stage renal disease. Genuine normo- betic nephropathy are possible in the diabetic clinic, all
tensive type 1 diabetic patients with diabetic nephropa- type 1 diabetic patients with diabetic nephropathy ac-
thy have an excellent kidney prognosis. cording to well-defined criteria [7] and who had a mini-
In 1976, Kussman, Goldstein and Gleason retrospec- mum of three years of follow-up of kidney function were
tively analyzed records from 112 type 1 diabetic patients included. In addition, to investigate regression of dia-
betic nephropathy as defined, a valid determination ofwith diabetic nephropathy [1]. The study led the authors
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the rate of decline in GFR is essential. The following substantial impact of blood pressure on the progression
of diabetic nephropathy.requirements should be fulfilled: The applied GFR
Patients in our study who obtained remission had amethod should have a good accuracy and precision [25].
slow rate of decline in GFR of only 2.2 mL/min/year.Repeated measurements of GFR (approximately every 6
The observation time was longer in the remission groupto 12 months) should be performed, and the observation
and tended to be longer in the regression group, as com-period should be extended to at least two years. These
pared with the no-remission/no-regression group, whichrequirements have been fulfilled in our prospective co-
possibly was caused by the design of the study. Patientshort study with a long-term follow-up. Since blood pres-
obtaining remission had a slow progression of kidneysure lowering is the only well-documented treatment
disease, and in the future will have longer follow-upmodality in diabetic nephropathy with respect to pro-
GFR measurements at our clinic, as opposed to the fastgression of renal disease [21], our data were analyzed
progressors who inevitably will progress to end-stage renalaccording to the blood pressure level obtained during
failure. Furthermore, we found that women are morethe observation period.
likely to obtain remission than men. Patients obtainingResults from observational studies are often consid-
remission as well as patients achieving regression haveered to overestimate treatment effects as compared with
an improved cardiovascular risk profile with lower bloodrandomized controlled trials. Conversely, according to
pressure and serum cholesterol values.two newly published studies it appears that well-designed
The logistic regression analysis revealed that lowercohort studies—such as ours—do not systematically over-
arterial blood pressure, reduced albuminuria, and betterestimate the magnitude of the effect of treatment as
glycemic control were predictors of regression of diabeticcompared with those in randomized trials on the same
nephropathy. A more thorough discussion of the impacttopic [26, 27].
of blood pressure, glycemic control, and hypercholester-Originally, long-term remission of nephrotic syn-
olemia has been given in detail previously [17]. However,drome, defined as remission from proteinuria above 3500
the success of a multifactorial intervention in delayingmg per 24 hours to below 1000 mg per 24 hours and
progression of diabetic microangiopathy has been dem-sustained below 1500 mg per 24 hours for at least six
onstrated in type 2 diabetic patients with microalbumin-months, and stabilization of serum creatinine, was dem-
uria [28]. There appear to be no substantial differencesonstrated during antihypertensive treatment in a small
between patients with type 2 diabetes and type 1 diabetessubset (6 of 103 patients) of type 1 diabetic patients with
with respect to initiation, progression, and treatment ofdiabetic nephropathy [23]. Recently, an extension of the
diabetic nephropathy [29]. Since several risk factors forCollaborative Study Group multicenter controlled trial
progression of diabetic nephropathy also seem important
of captopril therapy in patients with type 1 diabetes mel-
for regression of diabetic nephropathy in type 1 diabetic
litus and nephropathy reported that in patients random- patients, it is possible that aggressive multifactorial inter-
ized to the mean arterial blood pressure goal of 92 vention aimed at lowering blood pressure and albumin-
mm Hg, the level of proteinuria was significantly lower uria and improving glycemic control will induce regression
as compared with the patients randomized to a mean of diabetic nephropathy in a larger proportion of patients.
arterial blood pressure between 100 and 107 mm Hg A renoprotective effect of ACE inhibitors above and
[24]. Of the total of 126 patients, 40 (32%) achieved a beyond the effect of blood pressure lowering—an addi-
final total urinary protein excretion of less than 500 tional nonhemodynamic effect—has been demonstrated
mg/24 h. Among patients actually achieving a mean arte- in clinical trials [13, 30]. Moreover, ACE inhibitors have
rial blood pressure below 92 mm Hg, 27 patients (57%) been reported to have additional advantages in inducing
reached that level of albuminuria by the end of the study remission of nephrotic range proteinuria [23]. We could
after two years [24]. Thus, aggressive blood pressure not confirm this finding in our long-term prospective
treatment induces remission of proteinuria. observational study. However, our study design makes
A study in nondiabetic glomerulopathies using re- it difficult to conclude on this topic since we did not use
peated measurements of GFR with a plasma clearance a randomized design. Different patient categories could
technique showed that 10 out of 26 (38%) patients receive different antihypertensive treatment modalities.
treated with an ACE inhibitor for 20 to 60 months had Importantly, ACE inhibitors were not available until 1989.
a decline in kidney function comparable to the natural When applying the definition of regression of diabetic
aging process in healthy persons, that is, a regression of nephropathy as the normalization of the rate of GFR
nephropathy [22]. We have demonstrated that regression decline, the level of GFR is of importance for prolonged
is possible in 22% of our population of type 1 diabetic preservation of kidney function. Since all patients achiev-
patients with diabetic nephropathy (Fig. 2). Further- ing regression had preserved kidney function, it can be
more, the genuine normotensive patients have a slow concluded that the patients in regression, as defined in
our study, are unlikely to progress to end-stage renaldecline in GFR of 1.9 mL/min/year, emphasizing the
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phropathy in type 1 (insulin-dependent) diabetes: An epidemiolog-disease. To fully understand remission and regression
ical study. Diabetologia 25:496–501, 1983
of diabetic nephropathy, defined as moving the patient 7. Parving H-H, Andersen AR, Smidt UM, Svendsen PA: Early
aggressive antihypertensive treatment reduces rate of decline intoward normalization of the disease process and normal-
kidney function in diabetic nephropathy. Lancet 1:1175–1179, 1983ization in the rate of decline in GFR, respectively, it 8. Parving H-H, Andersen AR, Smidt UM, et al: Effect of antihyper-
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